162 related articles for article (PubMed ID: 36681658)
1. Binding and neutralizing antibody levels and vaccine efficacy/effectiveness compared between heterologous and homologous primary series COVID-19 vaccination: A systematic review and meta-analysis.
Angkasekwinai N; Prawjaeng J; Leelahavarong P; Khuntha S; Pheerapanyawaranun C; Chitpim N; Srinonprasert V; Chokephaibulkit K
Asian Pac J Allergy Immunol; 2022 Dec; 40(4):321-336. PubMed ID: 36681658
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.
Lv J; Wu H; Xu J; Liu J
Infect Dis Poverty; 2022 May; 11(1):53. PubMed ID: 35562753
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
Hu Y; Wang Y; Shao T; Tang W; Hu K; Zhou Y; Miao L; Liu J; Wang B; Yu W
Vaccine; 2023 May; 41(18):3003-3010. PubMed ID: 37037708
[TBL] [Abstract][Full Text] [Related]
4. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study.
Haase M; Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos-Araújo C; Veiga PM; Macario F
J Nephrol; 2022 Jun; 35(5):1467-1478. PubMed ID: 35084719
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet; 2021 Sep; 398(10303):856-869. PubMed ID: 34370971
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea.
Nham E; Ko JH; Song KH; Choi JY; Kim ES; Kim HJ; Kim B; Lim HY; Kim KC; Jang HC; Lee KH; Song YG; Baek YJ; Ahn JY; Choi JY; Kim YC; Park YS; Choi WS; Bae S; Kim SH; Kang ES; Jeong HW; Kim SW; Kwon KT; Kim SS; Peck KR
Front Immunol; 2022; 13():968105. PubMed ID: 36211416
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
[TBL] [Abstract][Full Text] [Related]
8. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
[TBL] [Abstract][Full Text] [Related]
9. Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay.
Orlandi C; Stefanetti G; Barocci S; Buffi G; Diotallevi A; Rocchi E; Ceccarelli M; Peluso S; Vandini D; Carlotti E; Magnani M; Galluzzi L; Casabianca A
Viruses; 2023 May; 15(5):. PubMed ID: 37243247
[TBL] [Abstract][Full Text] [Related]
10. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Shaw RH; Greenland M; Stuart ASV; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Libri V; Lillie PJ; Morey E; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; White R; Nguyen-Van-Tam JS; Liu X; Snape MD;
J Infect; 2023 Jun; 86(6):574-583. PubMed ID: 37028454
[TBL] [Abstract][Full Text] [Related]
11. To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination.
Chiu NC; Chi H; Tu YK; Huang YN; Tai YL; Weng SL; Chang L; Huang DT; Huang FY; Lin CY
Expert Rev Vaccines; 2021 Oct; 20(10):1211-1220. PubMed ID: 34415818
[TBL] [Abstract][Full Text] [Related]
12. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19.
Behrens GMN; Barros-Martins J; Cossmann A; Ramos GM; Stankov MV; Odak I; Dopfer-Jablonka A; Hetzel L; Köhler M; Patzer G; Binz C; Ritter C; Friedrichsen M; Schultze-Florey C; Ravens I; Willenzon S; Bubke A; Ristenpart J; Janssen A; Ssebyatika G; Krähling V; Bernhardt G; Hoffmann M; Pöhlmann S; Krey T; Bošnjak B; Hammerschmidt SI; Förster R
Nat Commun; 2022 Aug; 13(1):4872. PubMed ID: 35982040
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers.
Nah EH; Cho S; Park H; Kim S; Noh D; Kwon E; Cho HI
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992460
[TBL] [Abstract][Full Text] [Related]
15. Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial.
Bánki Z; Mateus J; Rössler A; Schäfer H; Bante D; Riepler L; Grifoni A; Sette A; Simon V; Falkensammer B; Ulmer H; Neurauter B; Borena W; ; Krammer F; von Laer D; Weiskopf D; Kimpel J
EBioMedicine; 2022 Jun; 80():104073. PubMed ID: 35617826
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.
Westrop SJ; Whitaker HJ; Powell AA; Power L; Whillock C; Campbell H; Simmons R; Warrener L; Ramsay ME; Ladhani SN; Brown KE; Amirthalingam G
J Infect; 2022 May; 84(5):692-700. PubMed ID: 35131335
[TBL] [Abstract][Full Text] [Related]
17. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Kelly E; Greenland M; de Whalley PCS; Aley PK; Plested EL; Singh N; Koleva S; Tonner S; Macaulay GC; Read RC; Ramsay M; Cameron JC; Turner DPJ; Heath PT; Bernatoniene J; Connor P; Cathie K; Faust SN; Banerjee I; Cantrell L; Mujadidi YF; Belhadef HT; Clutterbuck EA; Anslow R; Valliji Z; James T; Hallis B; Otter AD; Lambe T; Nguyen-Van-Tam JS; Minassian AM; Liu X; Snape MD;
J Infect; 2023 Sep; 87(3):230-241. PubMed ID: 37331429
[TBL] [Abstract][Full Text] [Related]
18. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
19. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingström J; Gordon M; Åberg M; Thålin C
Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35334989
[TBL] [Abstract][Full Text] [Related]
20. Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study.
Sim W; Kang H; Jung J; Lee J; Ko GY; Park HS; Choi J; Park K; Oh EJ
Front Immunol; 2023; 14():1120556. PubMed ID: 36936965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]